<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206917</url>
  </required_header>
  <id_info>
    <org_study_id>CL007</org_study_id>
    <nct_id>NCT04206917</nct_id>
  </id_info>
  <brief_title>MultiPulse Therapy (MPT) for AF</brief_title>
  <official_title>A Clinical Feasibility Study to Evaluate the Safety and Performance of Low‐Energy Therapy in Patients With Atrial Fibrillation Energy Therapy in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardialen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genae</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Five Corners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardialen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the clinical safety and feasibility of MultiPulse Therapy (MPT) electrical stimulation
      waveform sequence in terminating paroxysmal and persistent atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective non‐randomized feasibility study involving acute testing of MPT in subjects
      with paroxysmal and persistent AF during clinically indicated atrial fibrillation catheter
      ablation procedure.

      Subjects will be split into 2 cohorts depending on status at time of procedure.

        1. In Atrial Fibrillation at time of procedure (Clinical AF)

        2. In Normal Sinus Rhythm at time of procedure

      Subjects will be evaluated at the visits for the Clinically-Indicated Procedure per standard
      of care. A single follow-up at up to 30 days post-procedure is required to assess subjects
      for adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cardialen External Stimulation System (CESS) V1.0</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define the safety of MPT for the treatment of atrial fibrillation in subjects</measure>
    <time_frame>Study procedure and 30 day post procedure</time_frame>
    <description>Adverse Events from procedure and 30 day follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Translation</measure>
    <time_frame>Study procedure</time_frame>
    <description>Explore and enhance MPT parameters delivered in successful cases in a previous Cardialen AF study (CL001 / NCT02257112)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Translation</measure>
    <time_frame>Study procedure</time_frame>
    <description>Determine MPT parameters relationships at which MPT terminates AF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Translation</measure>
    <time_frame>Study procedure</time_frame>
    <description>Determine rate of conversion from AF to NSR after MPT delivery</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation, Paroxysmal</condition>
  <condition>Atrial Fibrillation, Persistent</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Multi Pulse Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi Pulse Therapy</intervention_name>
    <description>The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.</description>
    <arm_group_label>Multi Pulse Therapy</arm_group_label>
    <other_name>Unpinning Termination Therapy</other_name>
    <other_name>Multi-stage therapy</other_name>
    <other_name>Multi-stage electrotherapy</other_name>
    <other_name>MultiPulse Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between 18 and 80 years of age

          2. Willing and able to comply with the study protocol, provide a written informed consent

          3. Currently indicated for atrial catheter ablation due to paroxysmal or early persistent
             atrial fibrillation

          4. Current treatment and compliance with standard anticoagulation regimen, including
             uninterrupted OAC, with acceptable coagulation status, as determined by globally
             accepted risk stratification (CHA2DS2‐VASc score) and the Principal Investigator

        Exclusion Criteria:

          1. Life expectancy of 1 year or less

          2. AF due to reversible causes (e.g., hyperthyroidism, valve disease)

          3. History of DC Cardioversion which failed to convert to AF to Normal Sinus Rhythm

          4. Currently in AF for more than 3 months continuously

          5. Chronic, long‐standing persistent, or permanent atrial fibrillation

          6. Allergy or contraindication to anticoagulation therapy

          7. Presence of intracardiac thrombus (confirmed with TEE or ICE)

          8. Existing Left Atrial Appendage closure device

          9. Severely Dilated Left Atrium &gt;5cm

         10. LVEF&lt;20%

         11. NYHA Class IV heart failure at the time of enrollment

         12. History of embolic stroke, Transient Ischemic Attack (TIA) or other thromboembolic
             event within the preceding 3 months.

         13. Known hyper‐coagulable state that increases risk of thrombus

         14. History of myocardial infarction or coronary revascularization within the preceding 3
             months.

         15. History of sustained ventricular arrhythmia or cardiac arrest

         16. Presence of chronically implanted lead in the CS

         17. Presence of ventricular assist device, including intra‐aortic balloon pump

         18. Documented bradycardia (&lt;40 BPM) at the time of the study

         19. Morbid obesity: BMI&gt;39 kg/m2

         20. Presence of any prosthetic cardiac valve

         21. History of significant tricuspid valvular disease requiring surgery

         22. Moderate to severe mitral valve regurgitation (&gt;40% regurgitation fraction)

         23. Cognitive or mental health status that would interfere with study participation and
             proper informed consent

         24. Cardiovascular anatomical defects that would complicate placement of the stimulation
             leads required by the protocol, including congenital heart disease and cardiac vein
             anomalies per the Investigator's discretion

         25. Pregnancy confirmed by test within 7 days of procedure.

         26. Inability to pass catheters to heart due to vascular limitations

         27. Cardiovascular surgery or intervention within 1 month prior to enrollment or planned
             for up to 1 month after enrollment (other than the planned treatment procedure)

         28. No active endocarditis

         29. Any other medical condition which may affect the outcome of this study or safety of
             the subject as determined by the investigator

         30. History of hemodynamic compromise due to valvular heart disease

         31. Unstable CAD as determined by the investigator

         32. Severe proximal three‐vessel or left main coronary artery disease without
             revascularization as determined by the investigators

         33. History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia,
             Congenital Heart Anomaly, Cardiac Amyloidosis or Cardiac Sarcoidosis

         34. Any other condition which may affect the outcome of this study or safety of the
             subject as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dave Munneke, MS</last_name>
    <phone>6128049516</phone>
    <email>DMunneke@cardialen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Rasmussen, BA</last_name>
    <phone>7196596363</phone>
    <phone_ext>7196596363</phone_ext>
    <email>trasmussen@cardialen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Phillips, MD</last_name>
      <phone>+61 3255 7200</phone>
      <email>Karen.phillips@genesiscare.com</email>
    </contact>
    <contact_backup>
      <last_name>Sonia Nelson</last_name>
      <phone>+61 07 3858 8918</phone>
      <email>Sonia.nelson@genesiscare.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prashanthan Sanders, MD</last_name>
      <phone>+61 434 073 090</phone>
      <email>prash.sanders@adelaide.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Jun Lin</last_name>
      <phone>+61 8 8313 9000</phone>
      <email>jun.lin@adelaide.edu.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mulgrave Private Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Swale, MD</last_name>
      <phone>03 8809 6231</phone>
      <email>Matthew.Swale@genesiscare.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Ord</last_name>
      <phone>03 8793 3800</phone>
      <email>Michelle.Ord@genesiscare.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.cardialen.com/</url>
    <description>Sponsor</description>
  </link>
  <reference>
    <citation>Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014 Jan 7-14;63(1):40-8. doi: 10.1016/j.jacc.2013.07.098. Epub 2013 Sep 26.</citation>
    <PMID>24076284</PMID>
  </reference>
  <reference>
    <citation>Li W, Janardhan AH, Fedorov VV, Sha Q, Schuessler RB, Efimov IR. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):917-25. doi: 10.1161/CIRCEP.111.965830. Epub 2011 Oct 6.</citation>
    <PMID>21980076</PMID>
  </reference>
  <reference>
    <citation>Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm. 2006 Sep;3(9):1100-2. Epub 2006 Mar 10.</citation>
    <PMID>16945810</PMID>
  </reference>
  <reference>
    <citation>Ambrosi CM, Ripplinger CM, Efimov IR, Fedorov VV. Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. Heart Rhythm. 2011 Jan;8(1):101-8. doi: 10.1016/j.hrthm.2010.10.018. Epub 2010 Oct 19.</citation>
    <PMID>20969974</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

